Destiny Pharma plc

("Destiny Pharma" or "the Company")

2024 Annual General Meeting and Statement

Brighton, United Kingdom ‐ 12 June 2024 ‐ Destiny Pharma plc (AIM: DEST) a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life‐threatening infections, will today hold its 2024 Annual General Meeting (AGM) at 11am BST.

Ahead of the formal proceedings of the Meeting, Sir Nigel Rudd, Chairman of Destiny Pharma, will make the following statement:

"We continue to believe XF-73 Nasal has enormous market potential and can make a huge difference in the prevention of surgical site infections, and the reduction in the usage of antibiotics.

As announced in our Full Year Results, the Company and Board have been focused on seeking support to advance the XF-73 Nasal programme through Phase 3 clinical trials. While licencing activities continue, given our current cash runway, feedback from potential partners has led us to evaluate a range of strategic options. Our review of these options has continued since the Full Year Results and we intend to provide an update to the market in the coming weeks."

Immediately following the conclusion of the AGM, Chris Tovey, Chief Executive Officer of Destiny Pharma, will make a short corporate presentation that will be followed by a Q&A session.

Shareholders that wish to attend the AGM remotely should register for the event in advance by using the following link: https://www.investormeetcompany.com/destiny‐pharma‐plc/register‐investor

For further information, please contact:

Destiny Pharma plc

Chris Tovey, CEO

Shaun Claydon, CFO

+44 (0)1273 704 440

[email protected]

FTI Consulting

Ben Atwell / Simon Conway

+44 (0) 203 727 1000

[email protected]

Shore Capital (Nominated Adviser and Broker)

Daniel Bush / James Thomas / Lucy Bowden

+44 (0) 207 408 4090

About Destiny Pharma

Destiny Pharma is an innovative, clinical-stage biotechnology company focused on the development and commercialisation of novel medicines that can prevent life-threatening infections. The Company's drug development pipeline includes two late-stage assets XF-73 Nasal gel, a proprietary drug targeting the prevention of post-surgical staphylococcal hospital infections including MRSA and NTCD-M3, a microbiome-based biotherapeutic for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US.

For further information on the company, please visit www.destinypharma.com.

About XF-73 Nasal

XF-73 is the lead drug candidate from Destiny Pharma's XF platform, initially being developed for the prevention of post-surgical staphylococcal infections, such as methicillin-resistant Staphylococcus aureus (MRSA), which cause significant complications and increased healthcare costs in the hospital setting. XF‑73 has been awarded both Qualified Infectious Disease Product (QIDP) and Fast Track status by the US FDA.

Forward looking statements

Certain information contained in this announcement, including any information as to the company's strategy, plans or future financial or operating performance, constitutes "forward-looking statements". These forward looking statements may be identified by the use of forward-looking terminology, including the terms "believes", "estimates", "anticipates", "projects", "expects", "intends", "aims", "plans", "predicts", "may", "will", "seeks" "could" "targets" "assumes" "positioned" or "should" or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, objectives, goals, future events or intentions. These forward-looking statements include all matters that are not historical facts. They appear in a number of places throughout this announcement and include statements regarding the intentions, beliefs or current expectations of the Directors concerning, among other things, the company's results of operations, financial condition, prospects, growth, strategies and the industries in which the company operates. The Directors of the company believe that the expectations reflected in these statements are reasonable but may be affected by a number of variables which could cause actual results or trends to differ materially. Each forward-looking statement speaks only as of the date of the particular statement. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future or are beyond the company's control. Forward looking statements are not guarantees of future performance. Even if the company's actual results of operations, financial condition and the development of the industries in which the company operates are consistent with the forward-looking statements contained in this document, those results or developments may not be indicative of results or developments in subsequent periods.